| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human AREG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于 **AREG抗体(Amphiregulin抗体)** 的参考文献概览：
---
1. **文献名称**: *Amphiregulin confers resistance to anti-EGFR antibodies in colorectal cancer*
**作者**: Busser B, et al.
**摘要**: 该研究探讨了结直肠癌细胞中AREG过表达如何通过激活EGFR下游信号通路(如MAPK和PI3K/AKT)，导致对抗EGFR抗体(如西妥昔单抗)的耐药性。实验表明，使用AREG中和抗体可部分逆转耐药性。
2. **文献名称**: *Amphiregulin promotes skin inflammation via EGFR-ERK pathway in psoriasis*
**作者**: Pastore S, et al.
**摘要**: 研究揭示了AREG在银屑病皮肤炎症中的作用，发现AREG通过结合EGFR激活ERK信号通路，促进炎症因子释放。使用AREG中和抗体可显著减轻小鼠模型中的皮肤炎症和病理损伤。
3. **文献名称**: *Targeting Amphiregulin in HER2-positive breast cancer*
**作者**: Zaiss DM, et al.
**摘要**: 该文献报道了在HER2阳性乳腺癌中，AREG通过自分泌/旁分泌机制促进肿瘤生长和转移。实验显示，AREG特异性单克隆抗体能抑制肿瘤细胞增殖，并增强HER2靶向药物的疗效。
4. **文献名称**: *Amphiregulin blockade enhances antitumor immunity in combination with PD-1 checkpoint inhibitors*
**作者**: Kim S, et al.
**摘要**: 研究提出AREG通过抑制T细胞功能促进肿瘤免疫逃逸。在黑色素瘤模型中，AREG抗体联合PD-1抑制剂显著增强CD8+ T细胞浸润和抗肿瘤反应，为联合免疫治疗提供新策略。
---
以上文献涉及AREG抗体在 **癌症耐药性**、**炎症调控** 和 **免疫治疗** 中的应用，涵盖基础机制与临床前研究。如需具体期刊信息或年份，可进一步补充关键词检索。
**Background of AREG Antibodies**
Amphiregulin (AREG), a member of the epidermal growth factor (EGF) family, functions as a ligand for the epidermal growth factor receptor (EGFR). It plays critical roles in cell proliferation, survival, and differentiation by activating downstream signaling pathways such as MAPK and PI3K/AKT. AREG is involved in normal physiological processes, including tissue repair and epithelial homeostasis, but its dysregulation is linked to pathologies like cancer, inflammation, and fibrosis. In cancer, AREG overexpression promotes tumor growth, metastasis, and resistance to therapies, particularly in EGFR-driven malignancies (e.g., colorectal, lung, and breast cancers).
AREG antibodies are tools designed to target and modulate AREG activity. These antibodies can be monoclonal or polyclonal and are used in research to block AREG-EGFR interactions, thereby inhibiting oncogenic signaling. Therapeutic AREG antibodies are explored for their potential to suppress tumor progression or enhance chemotherapy efficacy. In inflammatory diseases (e.g., asthma, inflammatory bowel disease), AREG-neutralizing antibodies may mitigate immune hyperactivation by reducing pro-inflammatory cytokine production.
Additionally, diagnostic applications include detecting AREG levels in tissues or serum as biomarkers for disease progression or therapeutic response. Challenges remain in optimizing specificity and minimizing off-target effects. Ongoing research focuses on combination therapies and precision targeting to leverage AREG's dual role in tissue repair and disease pathogenesis.
×
